MDxHealth SA (MDXH.BR)
|Market Cap (Mil.):||€97.62|
|Shares Outstanding (Mil.):||34.25|
BRUSSELS, Nov 6 - Belgium-based cancer testing company MDxHealth said its revenues in the third quarter increased by more than 60 percent to 1.5 million euros ($2.02 million), as sales of its prostate cancer product ConfirmMDx rose sharply.
BRUSSELS, Oct 16 - Belgian-based cancer testing company MDxHealth said on Wednesday that its brain tumour test PredictMDx had been included in the guidelines of the U.S. National Comprehensive Cancer Network, meaning it would be made available to more U.S. patients.
BRUSSELS - Belgium-based cancer testing company MDxHealth said on Tuesday it had signed deal with two U.S. health insurers to expand coverage of its ConfirmMDx prostate cancer diagnosis by more than 50 million people.
BRUSSELS, Sept 3 - Belgian biotech firm MDxHealth has signed a deal with U.S. healthcare network Stratose, which will give its prostate cancer testing product access to one of the largest networks in the United States.
BRUSSELS - Belgium-based cancer testing company MDxHealth said on Monday it had signed a partnership with Bostwick Laboratories Inc to market prostate cancer test ConfirmMDx in the United States.
(Corrects in second paragraph to remove reference to company securing U.S. approval earlier this month; adds test available since May 2012.)
BRUSSELS, July 30 - MDxHealth SA : * TM) : MDxHealth establishes agreements with multiplan and three rivers
BRUSSELS, July 29 - Belgium-based cancer testing company MDxHealth said on Monday it had signed a partnership with Bostwick Laboratories Inc to market prostate cancer test ConfirmMDx in the United States.
BRUSSELS, July 1 - MDxHealth SA : * MDxHealth and Sumitomo sign pharmaco molecular diagnostic partnership
Earnings vs. Estimates
Analyst Research Reports
MDxHealth SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile